share_log

The Daily Biotech Pulse: Pfizer-BioNTech's COVID-19 Booster For Kids 5-11 Coming Soon, Ultragenyx In-Licenses Gene Therapy For Genetic Disorder, Ampio's AP-013 Trial Under Independent Investigation

Benzinga Real-time News ·  May 17, 2022 21:09

Here's a roundup of top developments in the biotech space over the last 24 hours:

Stocks In Focus

FDA May Authorize Pfizer-BioNTech's COVID-19 Booster For 5-11 Year Kids Soon: NYT

The FDA is expected to authorize a booster shot ofPfizer Inc(NYSE:PFE)/BioNTech SE's(NASDAQ:BNTX) COVID-19 vaccine for children ages 5 to 11, likely Tuesday, the New York Times reported, citing people familiar with the matter.

It is unclear how much demand there is for the third dose in the age group. According to the U.S. Centers for Disease Control and Prevention, just 28.8% of children ages...

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment